Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer
1997

Trial of Raltitrexed in Advanced Small-Cell Lung Cancer

Sample size: 21 publication Evidence: low

Author Information

Author(s): PJ Woll, R Basser, T Le Chevalier, P Drings, G Perez Manga, A Adenis, L Seymour, F Smith, N Thatcher

Primary Institution: CRC Department of Medical Oncology, Christie Hospital, Manchester, UK

Hypothesis

Is raltitrexed effective as a second-line therapy for advanced small-cell lung cancer?

Conclusion

Raltitrexed is inactive as a second-line therapy for advanced small-cell lung cancer.

Supporting Evidence

  • All patients had extensive disease and 17 had received prior therapy.
  • No objective tumour response was documented.
  • Only one of ten patients who received alternative cytotoxic regimens showed a response.
  • The median time to progression was 6 weeks.
  • The median survival from study entry was 15 weeks.

Takeaway

The study tested a drug called raltitrexed on patients with a type of lung cancer, but it didn't help them get better.

Methodology

Patients with advanced small-cell lung cancer received raltitrexed at a dose of 3 mg/m² as an intravenous infusion every 21 days.

Limitations

The study included only patients with chemoresistant disease, which may limit the generalizability of the results.

Participant Demographics

21 patients, 16 male and 5 female, median age 59 years.

Statistical Information

Confidence Interval

96% certainty that the response rate is < 20%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication